JP2019530440A5 - - Google Patents

Download PDF

Info

Publication number
JP2019530440A5
JP2019530440A5 JP2019512186A JP2019512186A JP2019530440A5 JP 2019530440 A5 JP2019530440 A5 JP 2019530440A5 JP 2019512186 A JP2019512186 A JP 2019512186A JP 2019512186 A JP2019512186 A JP 2019512186A JP 2019530440 A5 JP2019530440 A5 JP 2019530440A5
Authority
JP
Japan
Prior art keywords
seq
binding protein
chain variable
variable region
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019512186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530440A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/055281 external-priority patent/WO2018042385A2/en
Publication of JP2019530440A publication Critical patent/JP2019530440A/ja
Publication of JP2019530440A5 publication Critical patent/JP2019530440A5/ja
Withdrawn legal-status Critical Current

Links

JP2019512186A 2016-09-02 2017-09-01 インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物 Withdrawn JP2019530440A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662383237P 2016-09-02 2016-09-02
US62/383,237 2016-09-02
US201662440991P 2016-12-30 2016-12-30
US62/440,991 2016-12-30
US201762443509P 2017-01-06 2017-01-06
US62/443,509 2017-01-06
PCT/IB2017/055281 WO2018042385A2 (en) 2016-09-02 2017-09-01 Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments

Publications (2)

Publication Number Publication Date
JP2019530440A JP2019530440A (ja) 2019-10-24
JP2019530440A5 true JP2019530440A5 (OSRAM) 2020-10-08

Family

ID=61300216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019512186A Withdrawn JP2019530440A (ja) 2016-09-02 2017-09-01 インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物

Country Status (8)

Country Link
US (2) US11701384B2 (OSRAM)
EP (1) EP3506943B1 (OSRAM)
JP (1) JP2019530440A (OSRAM)
KR (1) KR20190057308A (OSRAM)
CN (1) CN109963590B (OSRAM)
AU (1) AU2017319702B2 (OSRAM)
CA (1) CA3039136A1 (OSRAM)
WO (1) WO2018042385A2 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
SI3240805T1 (sl) 2014-12-15 2025-04-30 The Regents Of The University Of California Bispecifični or-gate himerni antigenski receptor, odziv na cd19 in cd20
HK1255383A1 (zh) 2015-07-31 2019-08-16 The Research Institute At Nationwide Children's Hospital 去除生物膜的肽及抗體
CN108148863B (zh) * 2016-12-05 2019-12-17 上海优卡迪生物医药科技有限公司 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用
EP3565834B1 (en) 2017-01-04 2025-10-22 The Research Institute at Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
AU2018206552C1 (en) 2017-01-04 2025-04-10 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
CN112004577B (zh) 2018-03-14 2024-11-22 湖南思为康医药有限公司 用于降低毒性的免疫细胞修饰以及其在过继细胞疗法中的用途
JP7314161B2 (ja) * 2018-03-14 2023-07-25 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法
MX2021003838A (es) 2018-10-05 2021-05-27 Res Inst Nationwide Childrens Hospital Derivados de proteina hmgb1 para la eliminacion de biopeliculas.
AU2020205951A1 (en) * 2019-01-07 2021-07-22 Hunan Siweikang Therapeutics Co. Ltd Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy
EP3976644A4 (en) 2019-05-31 2022-12-14 The Johns Hopkins University BI-SPECIFIC LIAISONS
EP3976649A4 (en) * 2019-05-31 2022-12-14 The Johns Hopkins University B-SPECIFIC IL-6Ra/IL-8R BINDING AGENTS TO BLOCK MIGRATION OF CANCER CELLS
US12209118B2 (en) 2019-07-08 2025-01-28 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms
EP4543923A1 (en) * 2022-06-22 2025-04-30 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5543293A (en) 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
TW205553B (OSRAM) 1991-04-25 1993-05-11 Chugai Pharmaceutical Co Ltd
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5138941A (en) 1991-06-28 1992-08-18 Strauss Frederick J Wooden crusher for recyclable metal cans
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5591616A (en) 1992-07-07 1997-01-07 Japan Tobacco, Inc. Method for transforming monocotyledons
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
WO1994002620A2 (en) 1992-07-27 1994-02-03 Pioneer Hi-Bred International, Inc. An improved method of agrobacterium-mediated transformation of cultured soybean cells
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
AU5670194A (en) * 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5631146A (en) 1995-01-19 1997-05-20 The General Hospital Corporation DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
AU7274898A (en) 1997-05-07 1998-11-27 Bristol-Myers Squibb Company Recombinant antibody-enzyme fusion proteins
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
EP2386629A1 (en) 1997-10-14 2011-11-16 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP1430136A1 (en) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7066469B2 (en) 2002-08-06 2006-06-27 University of Kentucky Research Foundation Board of Supervisors of Louisiana State University Seal assembly for machinery housing
US20040043949A1 (en) 2002-08-30 2004-03-04 Christopher Richardson Therapeutic system targeting pathogen proteases and uses thereof
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
WO2004085611A2 (en) 2003-03-21 2004-10-07 The Research Foundation Of State University Of New York Model for mutually exclusive domain folding molecular switch
CA2533796A1 (en) 2003-08-01 2005-02-10 Amgen Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
EP1810980A1 (en) 2004-10-28 2007-07-25 Osaka University Interleukin-6 inhibitors
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
EP1850873B1 (en) 2005-02-08 2018-11-28 Genzyme Corporation Antibodies to tgfbeta
US20090068158A1 (en) 2005-12-09 2009-03-12 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
WO2007070866A2 (en) 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
EP3205723A1 (en) 2009-06-26 2017-08-16 i2 Pharmaceuticals, Inc. Expression of surrogate light chains
ES2686424T5 (es) * 2010-05-04 2023-03-27 Yeda Res & Dev Inmunoterapia con células alogénicas redireccionadas
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
KR20220070586A (ko) 2010-11-08 2022-05-31 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
AU2013326933B2 (en) 2012-10-04 2017-10-05 Research Development Foundation Serine protease molecules and therapies
EP2730289A1 (en) 2012-11-07 2014-05-14 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel immunoproteases
EP2922872B1 (en) 2012-11-21 2018-10-10 Janssen Biotech, Inc. Bispecific egfr/c-met antibodies
BR112015021595A2 (pt) 2013-03-11 2017-10-10 Genzyme Corp anticorpos anti-tgf-beta engenheirados e fragmentos de ligação do antígeno
ES2767423T3 (es) 2014-01-13 2020-06-17 Hope City Receptores de antígenos quiméricos (CARS) con mutaciones en la región del espaciador Fc y métodos para su uso
EP3105317B1 (en) 2014-02-14 2018-09-19 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
ES2737690T3 (es) 2014-02-27 2020-01-15 Ucl Business Ltd Variantes de APRIL
JP2017535284A (ja) 2014-11-05 2017-11-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞
CA2970466A1 (en) 2014-12-12 2016-06-16 Bluebird Bio, Inc. Bcma chimeric antigen receptors
WO2016130598A1 (en) 2015-02-09 2016-08-18 University Of Florida Research Foundation, Inc. Bi-specific chimeric antigen receptor and uses thereof
SMT202300027T1 (it) 2015-10-30 2023-05-12 Univ California Polipeptidi sensibili al fattore di crescita trasformante beta e le loro modalità d’uso
MX2018006789A (es) 2015-12-03 2019-02-13 Juno Therapeutics Inc Receptores quimericos modificados y composiciones y metodos relacionados.
KR20230148844A (ko) 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
CN105837693A (zh) 2016-05-30 2016-08-10 李斯文 一种基于bcma的抗原嵌合受体及其制备方法和应用
JP7114490B2 (ja) 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
AU2017366739B2 (en) 2016-12-02 2023-11-23 Angeles Therapeutics, Inc. Synthetic immune receptors and methods of use thereof
CN108148863B (zh) 2016-12-05 2019-12-17 上海优卡迪生物医药科技有限公司 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用
JP2020524512A (ja) 2017-06-21 2020-08-20 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法

Similar Documents

Publication Publication Date Title
JP2019530440A5 (OSRAM)
JP7115758B2 (ja) Ｃｄ１６ａ指向性ｎｋ細胞エンゲージメント用タンデムダイアボディ
CN110662560B (zh) 改进的抗原结合受体
RU2729401C2 (ru) Композиции и способы для иммунотерапии
JP2017531427A5 (OSRAM)
CN105189562B (zh) Il-15异源二聚体蛋白及其用途
Geering et al. Synthetic immunology: modulating the human immune system
CN108697736A (zh) 治疗性组合物和方法
CN110461357A (zh) 抗cd16a抗体与细胞因子的组合
JP2019511222A5 (OSRAM)
HRP20241228T1 (hr) T stanični receptori i imunološka terapija uporabom istih protiv pram pozitivnih karcinoma
JP2016505635A5 (OSRAM)
JP2018517431A (ja) 三重特異性結合タンパク質と使用方法
JP2015528003A5 (OSRAM)
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
FI3250592T3 (fi) Transtyretiinin vastaisia vasta-aineita
JP2016529229A5 (OSRAM)
JP7404279B2 (ja) 様々な構築物最適化を備えたｔ細胞抗原カプラ
JP2017536337A5 (OSRAM)
JP2018505893A5 (OSRAM)
CN113056283A (zh) 关于治疗血液肿瘤的工程化和非工程化γδ-T细胞的组合物和方法
US20230303660A1 (en) Co-stimulatory 4-1bbl ectodomain polypeptides for immunomodulation
US20230357355A1 (en) Cspg4-targeting humanized chimeric antigen receptor, immune effector cell expressing chimeric antigen receptor, and applications thereof
CN108350069A (zh) 针对il-23的多肽
CN103897057B (zh) 多价抗体片段与其三聚复合物